Can we count your visit with Google Analytics? No ads, no profiles. Details
ADVB
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Liquid biopsy / CTC detection is an emerging and high-value segment of precision oncology diagnostics; ADVB holds a proprietary microfluidic platform spanning enrichment through single-cell analysis, covering the full CTC workflow. A successful regulatory approval in Taiwan, China, or a Western market could catalyze a step-change in valuation for a company currently trading at ~$100M market cap with 21.6M shares outstanding.
ADVB is a pre-revenue development-stage company with accumulated deficits exceeding $19M. It faces entrenched competition from Foundation Medicine, Guardant Health, and others with far greater capital and clinical evidence bases. Regulatory timelines in multiple jurisdictions are uncertain, and the thin float (21.6M shares, very low daily volume) makes the stock highly illiquid and susceptible to extreme volatility.
No product has received full commercial approval as of mid-2026.
It reads our $ADVB data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.